Clinical Trial Update: A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase II randomized trial comparing lapatinib plus chemotherapy versus trastuzumab plus chemotherapy in HER2-positive and p95HER2-positive metastatic breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• P95her2-positive Breast Cancer

Drugs mentioned

• Lapatinib (Tykerb) (lapatinib)
• Trastuzumab (Herceptin) (trastuzumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 2 | Status: WITHDRAWN